Back to top
more

Neurocrine Biosciences (NBIX)

(Delayed Data from NSDQ)

$135.99 USD

135.99
717,575

-1.77 (-1.28%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $135.92 -0.07 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Has Lyra Therapeutics (LYRA) Outpaced Other Medical Stocks This Year?

Here is how Lyra Therapeutics, Inc. (LYRA) and Neurocrine Biosciences (NBIX) have performed compared to their sector so far this year.

What's in Store for United Therapeutics' (UTHR) Q2 Earnings?

United Therapeutics' (UTHR) investor focus is likely to have been on sales figures of Tyvaso, Remodulin and Orenitram in the second quarter, as these constitute a vast majority of the total revenues.

What to Expect From Molina Healthcare's (MOH) Q2 Earnings?

Molina Healthcare's (MOH) second-quarter results are likely to reflect benefits from higher premiums stemming from Medicaid and Medicare businesses, partly offset by elevated medical care costs.

Here's How Universal Health (UHS) Looks Ahead of Q2 Earnings

Universal Health's (UHS) second-quarter results are likely to benefit from sound contributions from Acute Care Hospital Services segment. Increased labor costs might partly hurt results.

Factors Likely to Shape Tenet Healthcare's (THC) Q2 Earnings

Tenet Healthcare's (THC) second-quarter results are likely to reflect the impact of lower contribution of the Hospital segment to overall revenues. The results might partly benefit from a downtrend in operating expenses.

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Smart Beta ETF report for FBT

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Smart Beta ETF report for FBT

Neurocrine Biosciences (NBIX) Lags Q1 Earnings Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of -57.58% and 1.97%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine Biosciences (NBIX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Smart Beta ETF report for FBT

NVIDIA and Neurocrine Biosciences highlighted as Zacks Bull and Bear of the Day

NVIDIA and Neurocrine Biosciences highlighted as Zacks Bull and Bear of the Day.

Kevin Cook headshot

Bear of the Day: Neurocrine Biosciences (NBIX)

Strong growth for Ingrezza meets company investment in the pipeline, sparking lowered EPS estimates

Neurocrine Biosciences (NBIX) Reports Q4 Loss, Misses Revenue Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of -113.11% and 1.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Neurocrine Biosciences (NBIX) to Report a Decline in Earnings: What to Look Out for

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Esperion (ESPR) Beats on Q3 Earnings, Lowers Expense Guidance

Esperion Therapeutics (ESPR) reports solid third-quarter results, beating estimates for earnings and sales. However, the stock declines in pre-market trading.

Neurocrine Biosciences (NBIX) Lags Q3 Earnings Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of -54.90% and 0.48%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neurocrine Biosciences (NBIX) Q2 Earnings Miss Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of -17.31% and 5.26%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Neurocrine Biosciences (NBIX) to Report a Decline in Earnings: What to Look Out for

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neurocrine Biosciences (NBIX) Q1 Earnings and Revenues Miss Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of -29.79% and -4.52%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Neurocrine Biosciences (NBIX) to Report a Decline in Earnings: What to Look Out for

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength Seen in Neurocrine (NBIX): Can Its 11.1% Jump Turn into More Strength?

Neurocrine (NBIX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.